222 related articles for article (PubMed ID: 25148033)
1. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Li X; Choi WW; Yan R; Yu H; Krasnoperov V; Kumar SR; Schuckman A; Klumpp DJ; Pan CX; Quinn D; Gill IS; Gill PS; Liu R
PLoS One; 2014; 9(8):e105326. PubMed ID: 25148033
[TBL] [Abstract][Full Text] [Related]
2. Identification of genes correlated with early-stage bladder cancer progression.
Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL
Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863
[TBL] [Abstract][Full Text] [Related]
3. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP
Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562
[TBL] [Abstract][Full Text] [Related]
5. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
[TBL] [Abstract][Full Text] [Related]
6. Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q; Suo Z; Risberg B; Karlsson MG; Villman K; Nesland JM
Pathol Oncol Res; 2004; 10(1):26-33. PubMed ID: 15029258
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
Messing EM
Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
[TBL] [Abstract][Full Text] [Related]
8. Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Lee TH; Heo JH; Jeong JY; Lee GH; Park DS; Kim TH
Yonsei Med J; 2021 Aug; 62(8):679-690. PubMed ID: 34296545
[TBL] [Abstract][Full Text] [Related]
9. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.
Patschan O; Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Lotan Y; Hotakainen K; Stenman UH; Bjartell A
World J Urol; 2012 Dec; 30(6):785-94. PubMed ID: 21739120
[TBL] [Abstract][Full Text] [Related]
10. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.
Xia G; Kumar SR; Stein JP; Singh J; Krasnoperov V; Zhu S; Hassanieh L; Smith DL; Buscarini M; Broek D; Quinn DI; Weaver FA; Gill PS
Oncogene; 2006 Feb; 25(5):769-80. PubMed ID: 16205642
[TBL] [Abstract][Full Text] [Related]
11. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
12. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.
Ozgür E; Heidenreich A; Dagtekin O; Engelmann U; Bloch W
Urol Oncol; 2011; 29(1):78-84. PubMed ID: 19272799
[TBL] [Abstract][Full Text] [Related]
13. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
Sun W; Zhang PL; Herrera GA
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
[TBL] [Abstract][Full Text] [Related]
14. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
15. EphB4 as a therapeutic target in mesothelioma.
Liu R; Ferguson BD; Zhou Y; Naga K; Salgia R; Gill PS; Krasnoperov V
BMC Cancer; 2013 May; 13():269. PubMed ID: 23721559
[TBL] [Abstract][Full Text] [Related]
16. BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells.
Huang YT; Lai PC; Wu CC; Hsu SH; Cheng CC; Lan YF; Chiu TH
Int J Oncol; 2010 Jun; 36(6):1469-76. PubMed ID: 20428771
[TBL] [Abstract][Full Text] [Related]
17. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
18. Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.
Ham WS; Lee JH; Yu HS; Choi YD
Urology; 2008 Oct; 72(4):921-6. PubMed ID: 18387660
[TBL] [Abstract][Full Text] [Related]
19. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
20. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells.
Nguyen TM; Arthur A; Hayball JD; Gronthos S
Stem Cells Dev; 2013 Oct; 22(20):2751-64. PubMed ID: 23711177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
